Episurf Medical submits IDE application to the US FDA for the Episealer® knee implant
Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached an important milestone on its strategy to reach the US market. The Investigational Device Exemption (IDE) application that the company has been working on is ready for filing. The application will now be filed to the US Food and Drug Administration (FDA) prior to the end of the second quarter. An approved IDE allows a medical device to be used in a clinical study in order to collect safety and effectiveness data for submission to the FDA. Episurf Medical is filing the IDE application for the Episealer® knee